Treat-to-Target in Rheumatoid Arthritis

Marcus H. Snow, MD, of the University of Nebraska Medical Center, discusses the importance of the treat-to target-strategy versus the non-targeted therapeutic approach in patients with rheumatoid arthritis.

Marcus H. Snow, MD, of the University of Nebraska Medical Center, discusses the importance of the treat-to target-strategy versus the non-targeted therapeutic approach in patients with rheumatoid arthritis.

Related Videos
Smiling Asian female pharmacist working in chemist shop or pharmacy | Image Credit: Atstock Productions - stock.adobe.com
sofiko14 / stock.adobe.com
Mammogram scans | Image credit: okrasiuk - stock.adobe.com
WP_7824 / stock.adobe.com
tilialucida / stock.adobe.com
vectorfusionart / stock.adobe.com
Related Content

FDA Approves Adalimumab-adaz High-Concentration Formulation Biosimilar

March 21st 2023

Pharmacy Focus: Psychedelic Pharmacy - Understanding Natural vs. Synthetic Psychedelics

January 13th 2023

Developing a Limited Distribution Plan for Oral Oncology Products

March 21st 2023

Pharmacy Focus: Public Health Matters- Celebrating American Pharmacist Month Part 2 with Autumn Zuckerman

October 13th 2022

Expert: Biosimilars May Not Be Cheap, But Are the ‘Very Minimum Helping to Make Cancer Therapies More Accessible Today’

March 14th 2023

FDA Approves Trofinetide for Treatment of Rett Syndrome in Adult, Pediatric Patients

March 13th 2023

FDA Approves Adalimumab-adaz High-Concentration Formulation Biosimilar

March 21st 2023

Pharmacy Focus: Psychedelic Pharmacy - Understanding Natural vs. Synthetic Psychedelics

January 13th 2023

Developing a Limited Distribution Plan for Oral Oncology Products

March 21st 2023

Pharmacy Focus: Public Health Matters- Celebrating American Pharmacist Month Part 2 with Autumn Zuckerman

October 13th 2022

Expert: Biosimilars May Not Be Cheap, But Are the ‘Very Minimum Helping to Make Cancer Therapies More Accessible Today’

March 14th 2023

FDA Approves Trofinetide for Treatment of Rett Syndrome in Adult, Pediatric Patients

March 13th 2023

FDA Approves Adalimumab-adaz High-Concentration Formulation Biosimilar

March 21st 2023

Pharmacy Focus: Psychedelic Pharmacy - Understanding Natural vs. Synthetic Psychedelics

January 13th 2023

Developing a Limited Distribution Plan for Oral Oncology Products

March 21st 2023

Pharmacy Focus: Public Health Matters- Celebrating American Pharmacist Month Part 2 with Autumn Zuckerman

October 13th 2022

Expert: Biosimilars May Not Be Cheap, But Are the ‘Very Minimum Helping to Make Cancer Therapies More Accessible Today’

March 14th 2023

FDA Approves Trofinetide for Treatment of Rett Syndrome in Adult, Pediatric Patients

March 13th 2023
© 2023 MJH Life Sciences

All rights reserved.